Journal of Education and Health Promotion

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 9  |  Issue : 1  |  Page : 6-

Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial


Gholam Reza Kheirabadi1, Zahra Yousefian1, Fatemeh Zargar1, Mahboobe Bahrami1, Mohammad R Maracy2 
1 Department of Psychiatry, Behavioral Sciences Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Dr. Mahboobe Bahrami
Department of Psychiatry, Behavioral Sciences Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan
Iran

BACKGROUND: Metacognitive therapy (MCT) is a new psychotherapy for depression. This study was conducted to compare the effectiveness of citalopram and MCT on major depressive disorders (MDDs). MATERIALS AND METHODS: A total of 36 patients with MDD were randomly assigned into three groups of citalopram (n = 12), MCT (n = 16), and control (n = 8). MCT group received ten sessions of metacognition therapy. Citalopram group received 20–40 mg citalopram, and the control group did not receive any interventions. Outcomes were measured using the Beck Depression Inventory-II, Metacognition Questionnaire-30, and Cognitive-Emotion Regulation (CER) Questionnaire. Data were analyzed with ANCOVA using SPSS version 18. RESULTS: Depression score reduction was significant in both citalopram and metacognitive groups (P < 0.05). However, there was only a statistically significant difference between MCT and control group in CER and metacognition. CONCLUSION: MCT and citalopram both are effective in symptom reduction in MDD. Furthermore, MCT could lead to more improvement in metacognition, depression symptoms, and CER than citalopram, when treating MDDs.


How to cite this article:
Kheirabadi GR, Yousefian Z, Zargar F, Bahrami M, Maracy MR. Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial.J Edu Health Promot 2020;9:6-6


How to cite this URL:
Kheirabadi GR, Yousefian Z, Zargar F, Bahrami M, Maracy MR. Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial. J Edu Health Promot [serial online] 2020 [cited 2020 Aug 9 ];9:6-6
Available from: http://www.jehp.net/article.asp?issn=2277-9531;year=2020;volume=9;issue=1;spage=6;epage=6;aulast=Kheirabadi;type=0